Purpose of review To summarize advances in next-generation sequencing and their application to breast and gynecologic cancer risk assessment.
INTRODUCTION
Following the identification in 1994 of BRCA1 and BRCA2, genetic assessment of breast and gynecologic cancer risk has become an increasingly important aspect of women's healthcare [1, 2] . In the last 2 decades, incremental advances in genetic testing, clinical risk assessment, and risk reduction strategies have transformed our approach to patients who seek advice about their probability of developing cancer. Since the emergence of the high-throughput, relatively inexpensive next-generation sequencing (NGS) technology and the 2013 US Supreme Court ruling against gene patenting, our understanding and practice of cancer genetics have undergone particularly rapid change. This review will summarize recent advances and current research priorities in clinical risk assessment for breast and gynecologic cancers.
LESSONS FROM THE BRCA1 AND BRCA2 ERA, 1994 ERA, -2013 The clinical application of genetic testing for mutations in BRCA1 and BRCA2 (BRCA1/2) has generated crucial observations and advances that shape our current approaches. Early studies [3, 4] of the cancer risks associated with a BRCA1/2 mutation were limited to families with an exceptionally high cancer burden, having multiple affected relatives, and very young ages at diagnosis; these analyses produced very high estimates of mutation-associated cancer risk (also known as 'penetrance'), approaching an 80-90% lifetime probability of developing breast cancer. Subsequent population-based studies [5, 6] of breast and ovarian cancer patients with BRCA1/2 mutations who were not selected for family history or early diagnosis have estimated far lower lifetime risks, with metaanalyses reporting risks for breast cancer of 57 and 49%, and for ovarian cancer of 40 and 18%, among BRCA1 and BRCA2 mutation carriers, respectively. This experience emphasizes the importance of using widely inclusive, population-based study cohorts to estimate cancer risks for the average carrier of a genetic mutation, rather than generalizing from smaller, highly selected clinic-based samples. Another major advance was the design and evaluation of targeted cancer risk reduction strategies for BRCA1/2 mutation carriers, including risk-reducing mastectomy and salpingo-oophorectomy and breast screening protocols that incorporate magnetic resonance imaging. Studies [7] [8] [9] have demonstrated a survival benefit due to these risk-targeted interventions, which have informed the development of evidence-based clinical practice guidelines and decision support tools [10,11 && ,12,13] , and now chart a pathway for other high-risk patient groups. The third noteworthy observation has been the economic and societal barriers that limit access to effective genetic testing. Due to the high costs of clinical BRCA1/2 testing (rising above $3000 during 1994-2013) and variable insurance coverage, racial/ ethnic minorities have been less widely tested than non-Hispanic Whites (NH Whites) in the United States. This access disparity has perpetuated a knowledge disparity about the normal sequence of BRCA1/2 among racial/ethnic minorities: African Americans, Asians, and Hispanics are far more likely to receive uninterpretable results [defined as variants of uncertain significance (VUS)] when they do undergo BRCA1/2 sequencing [14] . Although racial/ethnic disparities in clinical cancer genetics remain a significant problem, fears of genetic discrimination due to BRCA1/2 mutation carriage have been more effectively addressed. The Genetic Information Non-Discrimination Act of 2008 prohibits discrimination in health insurance or hiring and stipulates that mutation carriage may not be used as a preexisting condition by insurers. The Genetic Information Non-Discrimination Act and the related laws offer a protective legal infrastructure, which will be crucial for patients' well-being as the scope of genetic testing expands [15] [16] [17] .
NEXT-GENERATION SEQUENCING: AN ADVANCE IN TECHNOLOGY
NGS employs a massively parallel approach, enabling the rapid analysis of many genetic sequences at the same time. In comparison with traditional Sanger sequencing, NGS generates exponentially more genomic information at a dramatically lower cost. Whole-exome sequencing (WES) and wholegenome sequencing (WGS) are increasingly achievable at costs in the $1000 range (Fig. 1 ). Concerns about NGS have included its accuracy in sequence detection, which may fall short of the accuracy of older techniques and therefore require verification, and the sheer magnitude of data that it provides. Interpretation of NGS results, both in the genetics laboratory and in the clinic, currently lags behind the dramatic progress in sequencing methods [18, 19 && ]. In a departure from past decades when costs were limiting, challenges in results interpretation are now the primary barrier to widespread clinical dissemination of WGS.
MULTIPLE-GENE SEQUENCING PANELS FOR HEREDITARY CANCER RISK ASSESSMENT
Clinical trials of germline WES and WGS are underway in general medical and specialty settings, including oncology. As described above, however, routine clinical use of these comprehensive sequencing analyses is likely premature due to the volume and complexity of their results. In our present transition period from sequencing fewer to more genes, diseasefocused multiple-gene sequencing panels may offer a clinically useful compromise. Gene selection for existing multiple-gene panels has followed the published literature, including genes implicated in known cancer syndromes with a breast or gynecologic component (e.g., the Lynch syndrome genes: MLH1, MSH2, MSH6, PMS2, and EPCAM), genes with a moderate (approximately two-fold) breast and/or gynecologic cancer risk association (e.g., CHEK2 and ATM), and genes that function with or analogously to BRCA1/2 in DNA repair pathways (e.g., PALB2 and the Fanconi anemia-associated genes)
KEY POINTS
NGS produces large-volume genetic data quickly and cheaply, and multiple cancer-gene sequencing panels are rapidly emerging into clinical practice.
For approximately 4-16% of women who meet relevant practice guidelines yet test negative for BRCA1/2 mutations, NGS panels identify another cancer-associated gene mutation.
The complexity of gene panel selection and interpretation, including high rates of VUS, means that such testing is most effectively and safely conducted by an expert in cancer genetics.
Early clinical studies suggest that multiple-gene testing for breast and gynecologic cancer risk benefits appropriately selected patients.
Larger, longer-term studies of the clinical utility of NGS panels for breast and gynecologic cancer risk assessment are a major priority.
[18,20 [27] .
CLINICAL STUDIES OF NEXT-GENERATION SEQUENCING
Several studies have reported on the yield of multiple-gene panels for the assessment of breast and gynecologic cancer risk in relevant patient populations. Study subjects include ovarian cancer patients unselected for age at diagnosis or family cancer history [21, 28] ; families with striking breast/ ovarian cancer histories and/or young age at diagnosis [29] [30] [31] 
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Genes with an asterisk are associated with a known hereditary cancer syndrome and/or clinical practice guidelines; others are not.
Next-generation sequencing Kurian et al. . This finding reflects rapid progress in VUS classification algorithms as data accumulate regarding the sequences of less familiar genes. Nonetheless, even the lower end of multiple-gene panel VUS rates substantially exceeds VUS rates with testing BRCA1/2 only [14] . As observed with BRCA1/2 testing, multiple-gene panel VUS rates are significantly higher among racial/ethnic minorities than NH Whites, evincing a persistent health disparity that must be addressed [14, 31] .
Few studies to date have investigated the clinical outcomes of multiple-gene panel testing. We recently reported on the disclosure of multiple-gene sequencing results and the early outcomes of resulttargeted screening and prevention strategies among 198 women referred for clinical BRCA1/2 testing. All patients who were invited to receive their results of multiple-gene panel sequencing, which was conducted on a research protocol such that disclosure required recontacting and reconsenting of study participants, chose to do so. Initial risk-adapted interventions among 14 identified carriers of non-BRCA1/ 2 mutations included a screening colonoscopy that detected and removed a tubular adenoma, and thus probably prevented a cancer [33 && ]. These results suggest that multiple-gene panel testing may benefit appropriately selected patients, and larger, longerterm studies of clinical utility are a high priority.
GENETIC RESULTS COMMUNICATION AND COUNSELING
The emergence of NGS into clinical practice poses fundamental challenges to the existing process of results disclosure and genetic counseling. For breast and gynecologic risk assessment, the paradigm has shifted rapidly from a discussion of two genes (BRCA1/2) whose prevalence, penetrance, and management options have been extensively studied for 20 years, to panels of at least 15 [43] ; by contrast, we currently lack such reassuring data for noncarriers of familial mutations in other genes (e.g., CHEK2), and this uncertainty greatly limits the value of a 'true-negative' test result. Another challenging problem is how best to counsel patients who lack suggestive family cancer history, yet are found unexpectedly on multiple-gene panel testing to carry a high-risk gene mutation (e.g., CDH1). We do not know whether mutation carriers from such nonsyndromic families have the very high cancer risks that have previously been reported, nor whether they benefit from targeted risk-reducing procedures (e.g., prophylactic gastrectomy for CDH1 mutation carriers) [33 && ]. Furthermore, there is a major concern that patients, incorrectly believing a VUS to confer high cancer risk, will undertake invasive and irreversible prophylactic surgeries. This caveat is enhanced by evidence of rising bilateral mastectomy rates for breast cancer treatment in the last decade, in the absence of any survival benefit [44] [45] [46] . Moreover, a recent celebrity disclosure of BRCA1 mutation carriage and prophylactic mastectomy has precipitated public demand for genetic testing [47] [48] [49] , a phenomenon that compounds the danger of excessive intervention.
Given the increasing scope and complexity of NGS panels, it is strongly recommended that testing be conducted and interpreted by experts in cancer genetics [11 && ,18,20 & ,40] . Debate continues among insurers and professional societies as to the credentials and/or experience that practitioners must have to deliver high-quality care. Certified genetic counselors represent the gold standard for the practice of clinical cancer genetics, and training programs must expand to ensure a future workforce that is sufficient to meet patients' needs.
RESEARCH PRIORITIES
As discussed above, the clinical emergence of multiple-gene sequencing panels has generated more questions than answers to date. Major research priorities include the following:
(1) Which genes, and how many, should be included on breast and gynecologic cancer panels? International consortia will be required to answer these pressing questions; the existing Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA, http://enigmaconsortium.org/) and the new Prospective Registry for Outcomes of MultiPlex Testing (PROMPT, http:// www.promptstudy.org) exemplify two such efforts.
CONCLUSION
Next-generation germline sequencing panels for breast and gynecologic cancer risk assessment are increasingly used in clinic practice. Studies report a 4-16% prevalence of non-BRCA1/2 mutations in representative patient samples, along with early evidence of a clinical benefit from multiple-gene sequencing panels for appropriately selected patients. The uncertainty surrounding gene panel selection and results interpretation render cancer genetics expertise indispensable for good patient care. The many unknowns in this emerging field chart an exciting research agenda that will transform both our knowledge and our practice of clinical cancer risk assessment.
